ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of newly diagnosed large cell non-Hodgkin’s lymphoma

Incidence
- Large Cell Lymphoma constitutes 30–58% of non-Hodgkin’s lymphoma series. The crude incidence in the European Union is 3–4/100,000 per year. The incidence increases with age from 0.3/100,000 per year (35–39 y) to 26.6/100,000 per year (80–84 y).

Diagnosis
- Diagnosis should almost always be based on a surgical specimen/excisional lymph node biopsy providing enough material for fresh frozen and formalin-fixed samples. To ensure adequate quality, immediate processing by an experienced pathology institute has to be guaranteed.
- Fine needle aspirations or core biopsies may be appropriate as the only diagnostic test in the rare patients requiring emergency treatment or those not suitable for curative therapy.
- The histological report should give the diagnosis according to the WHO classification with use of CD20 immunohistochemistry.

Staging and risk assessment
- Patients amenable to curative therapy should have at least a chest X-ray and a CT-scan of the abdomen, as well as a bone marrow aspirate and biopsy. A diagnostic spinal tap directly combined with a first prophylactic instillation of cytarabine or methotrexate shall be considered in high-risk patients [patients with more than two adverse parameters according to international prognostic index (IPI)] with e.g. involvement of bone marrow, testis, the spine, or the base of the skull [V, D].
- A complete blood count, routine blood chemistry including LDH and uric acid as well as a screening test for HIV and hepatitis B and C are required. Protein electrophoresis is recommended for B-cell lymphomas.
- The staging is given according to the Ann Arbor system with mentioning of bulky disease [III, A]. For prognostic purposes, the IPI should be established [III, A].

Treatment plan
- A multidisciplinary treatment planning is required: Treatment with curative intent: CHOP-treatment combined with rituximab given every 21 days for usually 8 cycles is the current standard for CD20+ large-cell non-Hodgkin’s lymphoma of all stages [II, A]. In T-cell lymphoma, CHOP remains the standard. Shortening the interval between CHOP cycles to two weeks with growth factor support may be considered [II, B].
- High-dose chemotherapy with stem cell transplantation in poor risk patients remains experimental.
- Consolidation by radiotherapy to sites of bulky disease has not proven its benefit [III, C].
- Dose reductions due to hematological toxicity should be avoided and febrile neutropenia justifies prophylactic use of hematopoietic growth factors in patients treated with curative intent.

Response evaluation
- Adequate radiological tests should be done after 2 to 4 cycles and after the last cycle of CHOP or CHOP + radiotherapy, and whenever there are doubts regarding adequate response.
- An initially pathologic bone marrow aspirate/biopsy or spinal tap should be repeated at the end of treatment.
- Patients with incomplete or lacking response should be evaluated for early salvage regimens.

Follow-up
- History and physical examination every 3 months for 2 years, every 6 months for 3 more years, and then once a year with attention to development of secondary tumors [V, D]. High-risk patients still with curative options, such as high-dose chemotherapy with stem cell support, may mandate more frequent controls.
- Blood count and LDH at 3, 6, 12, and 24 months, then only as needed for evaluation of suspicious symptoms or clinical findings in those patients suitable for further therapy [V, D].
- Evaluation of thyroid dysfunction (TSH) in patients with irradiation to the neck at 1, 2, and at least at 5 years [III, A].
- After having received chest irradiation at premenopausal age, especially at an age below 25 years, women should be screened for secondary breast cancers clinically [III, A] and, after the age of 40–50 years, by mammography [III, C].
- Minimal adequate radiological examinations at 6, 12, and 24 months after end of treatment, by CT scan when indicated by site of disease [V, D].
Notes

Levels of Evidence [I–V] and Grades of Recommendation [A–D] as used by the American Society of Clinical Oncology are given in square brackets. Statements without grading were considered justified standard clinical practice by the experts and the ESMO faculty.

Literature


Coordinating authors for the ESMO Guidelines Task Force: L. M. Jost¹, O. Kloke² & R. A. Stahel³

¹Invited author and member of the task force, Oncology, Kantonsspital, CH-4101 Bruderholz/BL, Switzerland; ²Assigned task force member, Elisabeth Krankenhaus GmbH, Abt. Onkologie/Hämatoonkologie, Röntgenstrasse 10, 45661 Recklinghausen, Germany; ³Assigned task force member, Division of Oncology, University Hospital, Rämistrasse 100, CH-8091 Zürich, Switzerland


Correspondence to:
ESMO Guidelines Task Force
ESMO Head Office
Via La Santa 7
CH-6962 Lugano
Switzerland